Date: August 22, 2019
Time: 3:00pm EDT
Who should attend? PET Interpreters, Technologists, Referring Physicians, Marketers

In this session, Dr. Bridwell will:

• Detail the basic facts regarding Prostate cancer, including the U.S. incidence and prevalence, typical disease progression and range of treatments

• Provide an overview of PSMA PET isotopes, including their chemical make-up and method of action

• Note current research on the potential effectiveness of PSMA PET/ CT in staging patients with high clinical risk, as well as restaging those individuals with a biochemical or clinical failure after definitive initial therapy

• Discuss the theranostic potential of these agents, and the challenges of diagnostic imaging for this indication

Presenter: Robert S. Bridwell, MD, MBA SOFIE

Dr. Robert Bridwell, medical advisor to SOFIE, and co-founder of PETLinQ, is a board-certified physician in both Internal Medicine and Nuclear Medicine. He has extensive knowledge and experience in continuous quality improvement programs for PET and PET/CT imaging, utilizing physician empowerment training, protocol development assistance, and quality assurance guidelines. In the last five years, Dr. Bridwell has been invited to make numerous presentations, which have included more than 1200 hours of CME credit delivered to more than 350 institutions, 100 professional society meetings and more than 150 radiology groups throughout the United States, Canada and Europe.

Register now to receive a weblink:

NewsSeth Werkheiser